Suppr超能文献

术前前列腺特异性抗原倍增时间和速率是根治性前列腺切除术后结局的强有力且独立的预测指标。

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.

作者信息

Sengupta Shomik, Myers Robert P, Slezak Jeffrey M, Bergstralh Eric J, Zincke Horst, Blute Michael L

机构信息

Department of Urology and Division of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

出版信息

J Urol. 2005 Dec;174(6):2191-6. doi: 10.1097/01.ju.0000181209.37013.99.

Abstract

PURPOSE

Prostate specific antigen (PSA) is a useful marker for predicting outcomes following treatment for prostate cancer but, given the evolving nature of prostate cancer, there is an ongoing need to refine its use. We assessed preoperative PSA doubling time (PSADT) and PSA velocity (PSAV) as predictors of outcome following radical retropubic prostatectomy (RRP).

MATERIALS AND METHODS

We identified 2,290 men who were treated with RRP for prostate cancer between 1990 and 1999 with multiple preoperative PSA measurements available. PSADT was calculated by log linear regression and PSAV was calculated by linear regression. These parameters were used in preoperative and postoperative multivariate models for the end points of biochemical and clinical progression, and cancer death.

RESULTS

At a median followup of 7.1 years (range 0.1 to 14.5) biochemical progression, clinical progression and death from prostate cancer were observed in 583, 156 and 42 patients, respectively. The HR for death from prostate cancer was 6.22 (95% CI 3.33 to 11.61) in men with PSADT less than 18 months vs 18 or greater and 6.54 (95% CI 3.51 to 12.19) in men with PSAV greater than 3.4 ng/ml yearly vs 3.4 or less. On multivariate analysis adjusting for preoperative or postoperative variables PSADT and PSAV remained significant predictors of each outcome. When assessed jointly, PSAV was significant as a predictor of biochemical progression, while PSADT was a significant predictor of clinical progression and cancer death.

CONCLUSIONS

This study confirms the usefulness of preoperative PSA kinetics for predicting post-RRP outcomes, which may be useful for stratifying patients, so that rational management decisions can be made with respect to observation, intervention and adjuvant treatment. While PSADT maybe biologically more accurate and stronger on multivariate analysis, PSAV is clinically easier to use and a good approximation in the short term.

摘要

目的

前列腺特异性抗原(PSA)是预测前列腺癌治疗后结局的有用标志物,但鉴于前列腺癌的不断演变,持续需要优化其应用。我们评估了术前PSA倍增时间(PSADT)和PSA速率(PSAV)作为耻骨后根治性前列腺切除术(RRP)后结局的预测指标。

材料与方法

我们确定了1990年至1999年间接受RRP治疗前列腺癌的2290名男性,他们有多次术前PSA测量值。PSADT通过对数线性回归计算,PSAV通过线性回归计算。这些参数用于术前和术后多变量模型,以评估生化进展、临床进展和癌症死亡等终点。

结果

中位随访7.1年(范围0.1至14.5年),分别有583例、156例和42例患者出现生化进展、临床进展和前列腺癌死亡。PSADT小于18个月的男性前列腺癌死亡风险比(HR)为6.22(95%可信区间3.33至11.61),而PSADT为18个月或更长的男性为6.54(95%可信区间3.51至12.19);每年PSAV大于3.4 ng/ml的男性前列腺癌死亡HR为6.54(95%可信区间3.51至12.19),而PSAV为3.4 ng/ml或更低的男性为6.22(95%可信区间3.33至11.61)。在对术前或术后变量进行多变量分析调整后,PSADT和PSAV仍然是各结局的显著预测指标。联合评估时,PSAV是生化进展的显著预测指标,而PSADT是临床进展和癌症死亡的显著预测指标。

结论

本研究证实了术前PSA动力学对预测RRP术后结局的有用性,这可能有助于对患者进行分层,从而就观察、干预和辅助治疗做出合理的管理决策。虽然PSADT在生物学上可能更准确,在多变量分析中更强,但PSAV在临床上更易于使用,且在短期内是一个很好的近似指标。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验